Evidence map›Paper›PMID 32337183›Full record

ArticleJournal of biomedical physics & engineering2020

Rapid Delivery of Gold Nanoparticles into Colon Cancer HT-29 Cells by Electroporation: In-vitro Study.

Arab-Bafrani Z, Shahbazi-Gahrouei D, Abbasian M

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arab-Bafrani ZPhD, Stem Cell Research Center and Department of Medical Physics-Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Shahbazi-Gahrouei DPhD, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abbasian MPhD, Department of Biotechnology, College of Agriculture, Isfahan University of Technology, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElectroporation has become a routine technique for rapid drug delivery for the treatment of cancer. Because of its simplicity and wide range of application, it has been applied for the transfer of gold-nanoparticles and can facilitate entry into target cancer cells.

objectiveThe aim of this study is finding optimal conditions in order to obtain high GNPs- uptake and cell viability by means of electroporation. MATERIALS AND

methodsIn this in vitro study, exponential electrical pulse with electric field intensity ranging from 0.2 -2 kV/cm, pulse length of 100 µs and the pulse number of 2 was used. Electroporated cell viability was investigated using MTS assay and GNPs-cellular uptake was assayed using graphite furnace atomic absorption spectrometry (GFAAS). Finally, electroporation results were compared with passive method.

resultsThe maximum uptake occurred at 1.2 to 2 kV/cm and passive method happened. The cell viability of 1.2 kV/cm and passive method was about 90%, while the cell viability in 2 kV/cm drastically decreased to 50%. The findings showed that using two pulses of 1.2 kV/cm and 100 µs is a convenient way and surrogate of passive method for internalizing GNPs into cells.

conclusionIt is concluded that the electroporation-GNPs method could create an opportunistic context for colon cancer therapy. This type of treatment is especially attractive for highly immunogenic types of cancers in patients who are otherwise not surgical candidates or whose tumors are unresectable.

Indexed as

Cell SurvivalDrug DeliveryElectroporationGold NanoparticlesHT29 Cells

Identifiers

PMID32337183
PMCPMC7166215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.